Objectives: Bacterial skin and skin-structure infections (SSSIs) are frequent settings for antibiotic use. We surveyed their UK aetiology and pathogen susceptibility, including susceptibility to ceftaroline.
Introduction
Skin and skin-structure infections [SSSIs; or 'acute bacterial skin and skin-structure infections' (ABSSSIs) in FDA terminology 1 ] range from trivial to the life threatening. They are important in both hospitals and the community, with categorization complicated by the fact that hospital-acquired (e.g. post-surgical) SSSIs increasingly manifest in the community, following early hospital discharge. 2 Regulatory agencies categorize SSSIs as 'complicated' or 'uncomplicated' according to the depth of the structures involved, but in routine practice they are mostly categorized by type (cellulitis, surgical site, etc.). SSSI aetiology is dominated by Staphylococcus aureus, but other common isolates include b-haemolytic streptococci, enterococci, Enterobacteriaceae, anaerobes and Pseudomonas aeruginosa. 3 In a mixed flora, it is often difficult to distinguish pathogens and secondary colonists with confidence.
There is great variation in SSSI treatment, with 54 antibiotic regimens represented among 1995 SSSI patients at 129 hospitals. 4 Severity varies hugely too, with UK evidence suggesting that severe SSSIs are frequently under-treated, sometimes with adverse consequences, whereas mild infections are often over-treated. 5 Guiding principles are that the regimen should reflect: (i) the likelihood of a mixed flora, including Gram-negatives; (ii) the prevalence of MRSA; and (iii) severity, along with the potential consequences of failure. The prevalence of MRSA among bloodstream infections in the UK has been substantially reduced, but their residual prevalence in SSSIs is less clear. Multiple antibiotics-ceftaroline, dalbavancin, daptomycin, linezolid, oritavancin, quinupristin/dalfopristin, tedizolid and tigecycline-have been licensed for SSSIs since the turn of the century, all with anti-MRSA activity. 6 Most only act against Gram-positive pathogens, but ceftaroline and tigecycline also inhibit Enterobacteriaceae, but not P. aeruginosa.
We surveyed the current aetiology of SSSIs among hospitalized patients in the UK, considering MRSA prevalence in particular. In addition we ascertained: (i) the coverage offered by ceftaroline; and (ii) the extent to which the MIC distribution for MRSA is cut by EUCAST's 1 mg/L breakpoint (http://www.eucast.org).
Methods

SSSI survey
We recruited 40 UK laboratories, asking each to collect 60 consecutive clinically significant isolates from hospitalized patients with SSSI and to send these to PHE's Antimicrobial Resistance and Healthcare Associated Infections Reference Unit (AMRHAI). Collection ran from August 2012 to December 2013, and 35 sites contributed isolates (see the Acknowledgements section); 29 were in England, 3 in Scotland, 2 in Wales and 1 in Northern Ireland. Bacteria sought included S. aureus, b-haemolytic streptococci, enterococci, Enterobacteriaceae or non-fermenters. Anaerobes were excluded, as were: (i) commensal species likely to be contaminants, including coagulase-negative staphylococci, micrococci, propionibacteria and coryneforms; (ii) a-haemolytic staphylococci; and (iii) category III pathogens. Only one isolate per species per patient was permitted, except that MRSA and MSSA could be included if both were isolated from the patient. A case record form was sought for each isolate, collecting demographic and clinical data.
To expand the MRSA collection we also asked laboratories to submit a further 15 MRSA from SSSIs subsequent to their collection of 60 consecutive isolates.
Identification and susceptibility testing
Isolates were re-identified at AMRHAI as follows: S. aureus with Chromagar Staph aureus (Chromagar, Paris, France) and PCR for mecA 7 ; b-haemolytic streptococci by Lancefield typing using Streptococcal Grouping Latex Kits (Pro-Lab Diagnostics, Merseyside, UK); and enterococci and Gram-negative bacilli by MALDI-TOF MS (MALDI Biotyper, Bruker, Coventry, UK). MICs were determined by BSAC agar dilution on Iso-Sensitest agar (OxoidThermofisher, Basingstoke, UK), 8 except that isotonic agar with 50 mg/L Ca 2+ (Mast Laboratories, Bootle, UK) was used for daptomycin. Results were graded versus EUCAST breakpoints (http://www.eucast.org), which have been adopted by the BSAC. 9 Ceftaroline MICs additionally were determined by CLSI agar dilution 10 on Mueller -Hinton agar (Oxoid). Enterobacteriaceae found non-susceptible to ceftaroline (MIC .0.5 mg/L) and/or cefotaxime (MIC .1 mg/L) were subjected to ESBL tests, using BSAC agar dilution methodology to seek synergy between 4 mg/L clavulanate and cefepime, cefotaxime, ceftaroline or ceftazidime.
Antibiotic powders were obtained from suppliers as follows: ceftaroline (AstraZeneca, Macclesfield, UK); clavulanate (GlaxoSmithKline, Brentwood, UK); daptomycin (Novartis, Basel, Switzerland); linezolid and tigecycline (Pfizer, Sandwich, UK); cefepime (USP, Rockville, USA); quinupristin and dalfopristin (Nordic Pharma, Theale, UK); and ampicillin, benzylpenicillin, cefotaxime, ceftazidime, ciprofloxacin, clindamycin, erythromycin, gentamicin, oxacillin, tetracycline, teicoplanin and vancomycin (Sigma, Poole, UK).
Typing of S. aureus
MRSA with ceftaroline MICs ≥2 mg/L were spa typed as described by Harmsen et al. 11 with types assigned via the Ridom GmbH spa web site, http://www.spaserver.ridom.de. Multi-locus sequence type clonal complex (MLST -CC) assignments were inferred using the spa server (http://spa. ridom.de/mlst.shtml) and MLST database (http://saureus.mlst.net).
Results
The 35 laboratories contributed 11-60 isolates each, with a mean of 50 isolates/site and a total of 1908 consecutive organisms received. These were from 1756 patients: 1537 (87.5%) with a single pathogen and 219 (12.5%) with two or more pathogens; the latter total includes patients noted as co-infected with anaerobes, although these were not collected. We also received 329 supplementary MRSA. As these lacked denominator data, they were used only to add robustness to MIC distributions, and were excluded from epidemiological analyses. Pathogens in relation to hospital site and infection type S. aureus dominated, being present in 72.4% of infections sampled and the sole pathogen in 64.7%. It was present in 60% -100% of infections in each hospitalization category and each infection site (Tables 1 and 2 ) and was the sole pathogen in ≥57% of infections at each infection site and in all settings except intensive care (47%). Fully 944/1756 (53.8%) of patients had infections solely involving MSSA. MRSA accounted for 15.8% of S. aureus, with proportions exceeding 20% in general medicine, neurology and nephrology/renal patients and among S. aureus isolates from infected lines, infected sores and 'other' wounds. No MRSA were recovered from haematology/oncology or (unsurprisingly) obstetrics -gynaecology patients, and proportions were ,10% among S. aureus from burns units and burn infection, general surgery and surgical site infection patients. The MRSA rate among S. aureus isolates from general medicine patients (22.8%) was 2.5-fold that (9.3%) among general surgery patients, with this excess substantially reflecting large numbers of MRSA from traumatic wounds and infected ulcers and sores-groups where the MRSA proportion exceeded 20%. There was little major clustering when hospital site and infection type were combined (Table 3 ), but it is notable that more than half the general medicine MRSA were from ulcers and 'other' (i.e. non-surgical) traumatic wounds. MRSA proportions among S. aureus varied greatly with the hospital, from 0% to 68%; 10 sites had rates ,10%, 15 sites had rates of 10% -20%, 5 sites had rates of 20% -30% and 5 sites had rates .30%. These last five sites, two of them in Wales, accounted for 72/201 (36%) of the MRSA collected. Their distribution of clinical and ward/unit sites for MRSA resembled the generality of hospitals (not shown), suggesting that these excesses did not reflect different sampling approaches. Among the 201 MRSA patients, 192 had MRSA as Gen med, general medicine; Gen surg, general surgery; A&E/adm, accident and emergency/admissions unit; CoE, care of elderly; Ortho, orthopaedic; CTS, cardiothoracic surgery; Ob-gyn, obstetrics/gynaecology; Haem-onc, haematology/oncology; Neph/renal, nephrology or renal unit; NR, not reported; Derm, dermatology; Neuro, neurology. Klebsiella/Raoultella spp., 14 Serratia spp., 13 Citrobacter spp. and 11 indole-positive Proteeae, and were recovered from 252 patients (14.4%, with 17 having multiple species). In 179/252 cases (71.0%), Enterobacteriaceae were the sole pathogens; in the remainder they were co-present with other pathogens, predominantly S. aureus. Enterobacteriaceae were most frequent in general and orthopaedic surgery and intensive care patients, being present in .20% of surgical site infections, abscesses and (more surprisingly) line infections, but in ,10% of traumatic wound infections, infected ulcers, infected burns and infected dermatological conditions. Streptococci were submitted from 9.3% of patients; they comprised Lancefield B, C and G organisms (n ¼ 137) and Streptococcus pyogenes (n¼ 26). Prevalence was greatest in accident and emergency/admissions unit and care of the elderly patients and from infected ulcers and sores, cellulitis, infected dermatological conditions and diabetic lower extremity infections. Fewer than half (65/137) of the B, C and G streptococci were from monomicrobial infections versus two-thirds (17/25) of the S. pyogenes isolates.
Patient demographics and infection types
P. aeruginosa was recovered from 138 patients (7.9%) and was sole pathogen in 102. Rates were highest in ICU, renal, cardiothoracic surgery and haematology/oncology patients, whereas the prevalence rate in burns units (4.2%) and burn infections (6.1%) were low, despite the organism's predilection for this milieu. 12 Settings where P. aeruginosa was submitted from .10% of cases included line infections, 'other' wound infections, diabetic lower extremity infections and cellulitis. Enterococci (30 Enterococcus faecalis, 16 Enterococcus faecium and 1 Enterococcus raffinosus) were submitted from 37 (2.7%) of patients and were sole pathogens in 27. Proportions of patients with enterococci were highest (6.1% -8.3%) in burn infections and burns units; settings with the highest rates were unrelated to those with the highest Enterobacteriaceae rates, despite both being gut organisms with the same likely origin.
Antibiotic susceptibility
Susceptibility data are summarized by species group in Tables 4-6, with ceftaroline MIC distributions shown in Table 7 . MSSA, accounting for 56.1% of all isolates, were very susceptible, with even erythromycin and tetracycline active against .85% of isolates (Table 4) . MRSA were mostly resistant to erythromycin and ciprofloxacin, but were otherwise susceptible, as is typical of the EMRSA-15/CC22 and EMRSA-16/CC30 MRSA lineages predominant in the UK. 13 Daptomycin, linezolid, tigecycline and glycopeptides were active against .99% of both MRSA and MSSA. Ceftaroline at 1 mg/L was active against all MSSA irrespective of method, and against 97.5% of the MRSA by BSAC methodology or 94.0% by CLSI methodology. These latter proportions trivially altered to 98.0% and 95.1%, respectively, when the supplementary MRSA were included (Table 7) . MICs for all the ceftaroline nonsusceptible MRSA were 2 mg/L, representing the upper tail of a unimodal distribution, and counting as resistant by EUCAST criteria, though intermediate by those of the CLSI and FDA. The 25 SSSI epidemiology and ceftaroline in the UK 2847 JAC No bpt, no EUCAST breakpoint; NT, not tested. a Excludes supplementary MRSA-see Table 7 . b Based on results as found, though clindamycin should generally be avoided against all macrolide-resistant staphylococci and streptococci. MRSA with MICs of 2 mg/L by CLSI methodology included all 8 with an MIC of 2 mg/L by the BSAC method. Twenty-three were spa typed and all except one belonged to types corresponding to EMRSA-15/CC22 (n ¼ 10; spa types t022, t023, t032, t906, t747, t1977 and t3213) or EMRSA-16/CC30 (n ¼ 12; spa types t012, t018 and t253); the exception was a CC5 spa t045 isolate. All streptococci were susceptible to penicillin, ceftaroline, daptomycin, linezolid, tigecycline and glycopeptides (Table 4) . Resistance was only frequent to tetracycline (especially for group B/Streptococcus agalactiae) and erythromycin. MICs of ceftaroline were tightly clustered and unimodal, with values from 0.002 to 0.015 mg/L (Table 7) . Within this range, values were highest for group B/S. agalactiae and lowest for S. pyogenes. Among enterococci (Table 5) , 50% of E. faecalis and 33.3% of E. faecium had high-level gentamicin resistance and half the E. faecium isolates had glycopeptide resistance, always corresponding to the VanA phenotype, with both vancomycin and teicoplanin compromised. These high rates must be set against the overall infrequency of enterococci, which constituted ,2% of the collection. With one exception (MIC, 4 mg/L), E. faecium isolates were highly resistant to ceftaroline, but 25/30 E. faecalis were inhibited at 0.25 -1 mg/L, with MICs of 4 -8 mg/L for the remaining five. Bimodal MIC distributions were noted previously for E. faecalis with anti-MRSA cephalosporins, but remain unexplained. 14 E. coli constituted almost half the Enterobacteriaceae collected (125/269, 46.4%), with Enterobacter spp., Klebsiella spp. and P. mirabilis each constituting 12.5% -14.1%. Most of the resistance seen was of types inherent to particular species or genera (Table 6) . Thus, Klebsiella, Enterobacter, Citrobacter, Serratia and indole-positive Proteeae were mostly resistant to ampicillin and Citrobacter freundii, Enterobacter, Serratia and Morganella morganii to co-amoxiclav. Over 85% of isolates of each species were susceptible to gentamicin and ciprofloxacin. The behaviour of cephalosporins was more complex, and was investigated for all 45 isolates with ceftaroline MICs .0.5 mg/L. These could be divided into three groups (Table 8 ). The first comprised 15 isolates-mostly E. coli and K. pneumoniae-deduced to have ESBLs based on synergy between all cephalosporins and clavulanate. These were all were substantially resistant to ceftaroline, with MICs .16 mg/L, and to cefotaxime; many were also multiresistant to gentamicin and ciprofloxacin. The second group comprised 16 isolates-mostly Enterobacter, C. freundii, M. morganii and Serratia-with greater resistance to cefotaxime, ceftazidime and ceftaroline than to cefepime, to which 13/16 remained susceptible. Cephalosporin MICs for these isolates were not reduced by clavulanate. This combination of cefepime susceptibility and clavulanate-independent resistance implied high-level AmpC activity. MICs of ceftaroline for these isolates ranged from 2 to .256 mg/L, with 13/16 values ≥8 mg/L. The final group of 14 isolates had low-level ceftaroline resistance (MIC 1 -16 mg/L) and were susceptible to the other three cephalosporins or had only intermediate resistance, with MICs never exceeding 2 mg/L: 6 were E. coli and 6 were Serratia spp.; ceftaroline MICs for the E. coli isolates were reduced by clavulanate to ≤0.12 mg/L; those for the Serratia spp. were raised by clavulanate in many cases, implying AmpC induction. Overall, ceftaroline retained activity against 83.3% of Enterobacteriaceae isolates, with .80% susceptibility except among Enterobacter (68.4%) and Serratia spp. (35.4%). No Enterobacteriaceae were nonsusceptible to cefotaxime but susceptible to ceftaroline.
For P. aeruginosa, susceptibility rates to ceftazidime, gentamicin and ciprofloxacin all exceeded 90%, confirming the pattern of infrequent resistance outside chronic respiratory infections that is typically seen in the UK.
Ceftaroline MICs by BSAC versus CLSI methodology
Ceftaroline MICs of 2 mg/L were found for a greater, but still small, proportion of MRSA by CLSI methodology than by BSAC methodology (Table 7) . This followed a wider pattern whereby, in .97% of cases excluding P. aeruginosa, MICs of ceftaroline by CLSI methodology equalled those on Iso-Sensitest agar, or were 2-fold higher (Table 9 ). For P. aeruginosa the differential was 4 -16-fold; reasons are unclear and the point is academic, since the species is universally agreed to be inherently resistant, with no breakpoints assigned.
Discussion
We sought to define the current aetiology of SSSIs in the UK, the residual prevalence of MRSA, and the activity of ceftaroline. The study aimed to provide a large snapshot, but two caveats should be noted: (i) recording of ward type by participating laboratories is probably more accurate than recording of infection type, since laboratories know where a specimen has come from, but depend 15 This may reflect differing norms in recording secondary organisms and our exclusion of coagulase-negative staphylococci, which were included as pathogens or co-pathogens in some surveys, though not generally in Phase III SSSI data. Despite these caveats, the unit and clinical site analyses presented in Tables 1 and 2 are mutually consistent with, similar aetiology across, e.g. surgical site infections and the general and orthopaedic surgery groups, and between burn infections and burns unit patients.
The species distribution, with S. aureus dominating in all subsets, agrees with that reported by Lipsky et al., 3 though percentages differ partly because Lipsky et al. 3 accepted CoNS as significant, to the extent of including them as the sole pathogens in 18.2% of infections. S. aureus was sole pathogen in 54.7% of Lipsky's monomicrobial SSSIs, rising to 66.8% if CoNS were discounted, compared with 64.7% here. Proportions of monomicrobial infections with Enterobacteriaceae, streptococci (pooled), P. aeruginosa and enterococci were 10.1%, 9.5%, 3.1% and 3.5%, respectively, in Lipsky's series, rising to 12.3%, 11.6%, 3.8% and 4.3% once CoNS were disregarded, compared with 10.1%, 4.7%, 5.8, 1.5% here. Another study of 527 patients with healthcare-associated complicated SSSIs 16 found S. aureus in 48.6%, enterococci in 14.6% and P. aeruginosa in 10.1%, whilst the SENTRY surveillance found that S. aureus accounted for 45.9% of SSSI pathogens and P. aeruginosa for 10.8%. 17 Recent Phase III antibiotic trials in complicated SSSI/ABSSSI 18, 19 again show a similar distribution, with S. aureus in more than half the patients and with b-haemolytic streptococci, P. aeruginosa and Enterobacteriaceae in 5%-20% each, compared with enterococci in ,5%. The one radically different report is PHE's surgical site surveillance for English hospitals in 2013 -14, 20 which indicates a much lower proportion of S. aureus (16%, or 18.4% if rebased to exclude CoNS), with Enterobacteriaceae dominant (26%, or 30% if rebased to exclude CoNS). The dominance of Enterobacteriaceae derived from their high proportion (56.7%) in infection following bowel surgery, where only 13.0% of patients had S. aureus. S. aureus remained the major pathogen in the PHE orthopaedic surgery series, in which it was present in 54.5% -64.3% of monomicrobial infections. The difference between the low rate of S. aureus in the PHE bowel surgery series and the high rate in the present general surgery group (which should heavily represent infections following bowel surgery) remains unexplained.
Importantly, aside from underscoring the dominance of S. aureus, the present analysis shows: (i) that SSSIs in ICUs had a more diverse aetiology than those in other patient groups, with Enterobacteriaceae and P. aeruginosa more prevalent; (ii) that Enterobacteriaceae were also prominent in general and orthopaedic surgery patients and in their surgical site infections; (iii) that, more surprisingly, Enterobacteriaceae were prevalent in line infections; and (iv) that streptococci, which were mostly B, C and G types, were most prevalent in emergency and admissions unit patients, care of the elderly patients and cellulitis patients, whereas Enterobacteriaceae were rare pathogens in emergency and admissions unit SSSI patients and care of the elderly patients. Such data, together with information on MRSA prevalence, point to settings where broad-spectrum therapy may be desirable in the empirical management of SSSIs. Ceftaroline may have a particular potential in mixed SSSIs that involve MRSA together with Enterobacteriaceae, but these are now rare in the UK: only 9/201 MRSA were from mixed infections and these largely had 'unknowns' or P. aeruginosa as the second isolate, not Enterobacteriaceae.
Rates of resistance were low. Fully 944/1756 patients had monomicrobial MSSA infections. Only 15.8% of S. aureus isolates were MRSA and among general surgery patients the MRSA rate was ,10%. This contrasts with a 61% MRSA rate among S. aureus from surgical site infections in England in 1997-99 21 and doubtless reflects the success of subsequent MRSA reduction programmes, which have also seen a .85% reduction in MRSA bacteraemias in England since their 2003/4 peak. 22, 23 Other 24 The higher MRSA rate in general medicine-two and a half times that in general surgery-was associated with infected ulcers and 'other' traumatic wounds ( Table 3 ). The proportion of MRSA was higher in particular hospitals, with 5/35 hospitals accounting for 35% of MRSA. Two of these five sites were in Wales, which had risk-based pre-admission MRSA screening during the survey period rather than universal screening, as then applied in England. Among other common pathogens, streptococci were universally susceptible, except to tetracycline and erythromycin, whilst .90% of Enterobacteriaceae were susceptible to ciprofloxacin and gentamicin and .80% were susceptible to cephalosporins. Over 90% of P. aeruginosa were susceptible to ciprofloxacin, gentamicin and ceftazidime.
Fully 97.5% (98.3% with supplementary isolates) of collected MRSA were susceptible to ceftaroline by BSAC methodology, with this proportion falling to 94.0% (95.1%) by CLSI methodology. Typing found little that was exceptional about the resistant isolates; almost all of these belonged to the EMRSA-15/CC22 and EMRSA-16/CC30 lineages, which have long been dominant among HA-MRSA in the UK. 3, 25 MICs never exceeded 2 mg/L, whereas values of 4 mg/L have been seen for small minorities of isolates in Greece and Germany, with some of these being shown to harbour PBP2
′ mutations. 26, 27 Predictably, ceftaroline lacked activity against Enterobacteriaceae that were resistant to cefotaxime and that had profiles indicating ESBLs or derepressed AmpC. Resistance was seen also in a few further Enterobacteriaceae that lacked clear resistance to other cephalosporins; these predominantly comprised E. coli with ceftaroline/clavulanate synergy and Serratia spp. with ceftaroline MICS of 1 mg/L; the former group is in keeping with the observation that high-level expression of classical TEM enzymes confers low-level protection against ceftaroline; 14 the second simply reflects Serratia spp. being inherently less susceptible than other Enterobacteriaceae (mode MIC 1 mg/L versus 0.12-0.25 mg/L for other genera; Table 6 ), with the tail of the normal distribution thus being cut by the breakpoint.
In summary, these data provide a snapshot of the aetiology of SSSIs in the UK, indicating the dominance of MSSA and the settings where MRSA is now concentrated. In most cases, multiple treatment options remain and narrow-spectrum anti-Grampositive therapy is appropriate. Ceftaroline offers potential in the now less common situation where combinations of MRSA and Enterobacteriaceae are present.
